BioCryst Pharmaceuticals | BCRX - Current Assets


BioCryst Pharmaceuticals reported $484.68M in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
Alnylam Pharmaceuticals USD 4.62B 400.86M Jun/2026
BioCryst Pharmaceuticals USD 484.68M 111.06M Jun/2026
Chugai Pharma JPY 1.7T 164.75B Jun/2026
Daiichi Sankyo JPY 2.23T 91.92B Jun/2026
DBV Technologies USD 201.9M 44.8M Jun/2026
Enanta Pharmaceuticals USD 198.68M 5.65M Dec/2025
Gilead Sciences USD 12.53B 6.11B Jun/2026
GlaxoSmithKline GBP 17.56B 202M Jun/2026
Glaxosmithkline GBP 17.76B 5.83B Mar/2026
Incyte USD 6.03B 542.31M Jun/2026
Ionis Pharmaceuticals USD 2.49B 446.73M Jun/2026
Karyopharm Therapeutics USD 126.33M 23.19M Mar/2026
Neurocrine Biosciences USD 1.64B 798.6M Jun/2026
Novavax USD 771.1M 79.72M Jun/2026
PTC Therapeutics USD 2.62B 363.36M Jun/2026
Regeneron Pharmaceuticals USD 18.45B 236.8M Jun/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Sarepta Therapeutics USD 2.22B 86.05M Jun/2026
Ultragenyx Pharmaceutical USD 606M 51M Jun/2026
Vertex Pharmaceuticals USD 12.54B 813.4M Jun/2026